fosaprepitant,pembrolizumab
merck
['kn-716', 'melanoma', 'emend']
first #melanoma session at #asco22 and tremendous new approaches and information with direct clinical implications:
1. updated results of the kn-716 study at ia3 with the dmfs data, clearly showing the dmfs benefit in pts with stage iib/iic melanoma - no new tox but still 1/1 
Dermatologist | Attending Physician Dermato-Oncology, Skin Cancer Unit, University Hospital of Zurich | MD PhD Candidate Clinical Science UZH